Semaglutide, a type of GLP-1R agonists with 94% sequence homology to GLP-1 and with an extended half-life of approximately 1 week, has been clinically approved to treat T2DM and is available in subcutaneous and oral dosage form (136, 137). This evidence concerns the gene GCG and type 2 diabetes mellitus.